DataLily vs Serif Health
DataLily Insights vs Serif Health: which fits your team?
Updated · Competitor facts verified from public sources
The short answer
DataLily Insights is built for ASC decisions: Rose, a built-in AI analyst, answers plain-language questions on payer contract negotiation, finding surgeons for a center, and build-versus-buy, ending each answer in a charted recommendation instead of a table you still have to interpret. Serif Health, by contrast, is price-transparency infrastructure for teams that live in negotiated rates, payers, health systems, and employers benchmarking reimbursement across payers and regions. It is not ASC-decision-native.
Built for
ASC administrators, physician-owners, and investors making surgery-center decisions
Payers, health systems, employers, and life sciences teams working with negotiated rates
Interface
Ask Rose in plain language, get a charted answer that ends in a recommendation
Web platform, API, and bulk data feeds; Signal Ask NL agent in limited beta
Core jobs
Payer contract negotiation, finding providers for an ASC, build or buy a center
Rate search, market benchmarking, network and cost-of-care analysis
Rate benchmarking
One input among many, run across DataLily's proprietary dataset
Core product; deep MRF rate benchmarking across payers and regions
Provider-level intelligence
Surgeons and groups across 10M+ providers
Provider and regional tagging focused on reimbursement rates
Time to answer
Ask a question, get a charted recommendation back
Query returns rate data and benchmarks to analyze
Best if
You need to make an ASC decision, not just pull a data table
You want deep negotiated-rate benchmarking infrastructure
Serif Health details verified from public sources on . Re-checked each quarter.
Where Serif Health is strong
Serif Health is a price-transparency platform whose flagship product, Signal, launched in 2023 and is used by 200+ organizations. Its negotiated-rate benchmarking spans 200+ commercial payers and 5,000+ hospitals, exposed through a web platform, API, and bulk data feeds, with published entry pricing starting around $1,000 per month per US region. It is built for rate benchmarking across payers and regions, not for ASC business decisions.
Where DataLily is different
DataLily Insights is ASC-native, not a general rate-transparency tool that surgery centers adapt. You ask Rose, the built-in AI analyst, a question in plain English, and every answer comes back charted and ends in a recommendation, not a table you still have to model yourself. The jobs are the ones ASC operators actually run: benchmark what each payer pays for your highest-volume CPTs before a renewal and flag which contracts to reopen first; source active, high-volume independent surgeons to recruit or co-develop a center around; and score markets on provider density, saturation, payer mix, and case-mix fit to decide where to build or whether to buy. Rate benchmarking is one input, run across DataLily's proprietary dataset of 100B+ data points spanning 10M+ providers, alongside provider-level intelligence on surgeons and groups. Teams selling into ASCs can also rank a territory by case volume, specialty mix, ownership, and who actually signs. The output is a decision delivered in the time it takes to ask, replacing a weeks-long data project, and DataLily deliberately stays out of RCM and the payer side.
How to decide in one meeting
Bring the same three real ASC questions to both demos: is this payer's renewal offer below or above market, which independent surgeons should we recruit, and should we build a second OR or partner. Ask each product to answer end to end. Serif Health will return strong negotiated-rate benchmarks; DataLily hands you a chart plus a recommendation on what to do next, which is what an ASC operator, owner, or investor actually needs to decide.
FAQ
Frequently asked questions
Is DataLily Insights a Serif Health alternative?
Does Serif Health have natural-language querying?
What does Serif Health cost?
Can DataLily benchmark payer rates like Serif Health?
Ask Rose
Ask Rose: "Our top commercial payer just sent a renewal offer. Show me how our rates for our highest-volume CPTs compare to market for outpatient surgery in our region, and tell me whether to accept, counter, or walk."
More comparisons
See Rose on your own market
Bring your three real questions — we'll answer them in the room.